Arrhythmias & electrophysiology
Mortality and ventricular arrhythmias in patients on d,l-sotalol for rhythm control of atrial fibrillation: A nationwide cohort study
Authors' conclusion
There was no excess mortality with d,l-sotalol compared with cardioselective beta-blockers in patients undergoing rhythm control treatment for AF after a second cardioversion.
Study context
- Population
- Atrial fibrillation (AF) patients undergoing rhythm control after a second cardioversion, Swedish National Patient Registry (2006–2017)matched cohort n = 4953 per group
- Participants
- 4,987 vs 27,078
- Exposure
- d,l-sotalol vs cardioselective beta-blockers for rhythm control
- d,l-sotaloln = 4,987
- Beta-blockern = 27,078reference
- Outcome
- All-cause mortality
- Follow-up
- Mean 458 days
Methodological detailspopulation-based, nationwide, propensity-score matched
- Population-based
- Nationwide
- Propensity-score matched
Main finding
As reported in the abstract
d,l-sotalol vs Beta-blockerAdjusted hazard ratio (95% CI)
Overall cohort
0.66(0.52–0.83)
Propensity score matched cohort (n = 4953 each)
0.63(0.48–0.86)
Observational data: associations, not effects.
Safety
Composite of cardiac arrest/death and ventricular arrhythmias · mean follow-up 458 days
- No differences in the composite outcome
- Propensity score matched cohort (n = 4953 in each group)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Mortality and ventricular arrhythmias in patients on d,l-sotalol for rhythm control of atrial fibrillation: A nationwide cohort study. Heart Rhythm. Published 19 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →